IMT-2021-0002_supplementaryfigure2.docxSupplementary Material - Pretreatment Lung Immune Prognostic Index as biomarker in NSCLC cancer patients receiving first line pembrolizumabSupplementary Material - Pretreatment Lung Immune Prognostic Index as biomarker in NSCLC cancer patients receiving first line pembrolizumab
|
|
Abstract Aims Investigate the role of pretreatment Lung Immune Prognostic Index (LIPI) as biomarker in PDL1≥50% NSCLC patients receiving pembrolizumab. Patients and methods We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient we evaluated 1-year overall survival (OS) and progression free survival (PFS) rate. C-statistic and survival ROC curves were used to study discrimination of LIPI. Results After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year PFS rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p<0.001). The c-statistic and AUC of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively. Conclusions |
Supplementary Figure 1. OS according to LIPI groups. Supplementary Figure 2. PFS according to LIPI groups.
Abstract Aims Investigate the role of pretreatment Lung Immune Prognostic Index (LIPI) as biomarker in PDL1≥50% NSCLC patients receiving pembrolizumab. Patients and methods We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient we evaluated 1-year overall survival (OS) and progression free survival (PFS) rate. C-statistic and survival ROC curves were used to study discrimination of LIPI. Results After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year PFS rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p<0.001). The c-statistic and AUC of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively. Conclusions |
